Please assess the completion status of the following clinical trial:

Trial Title: S9912 Combination Chemo in Stage III Ovarian Cancer,

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage III ovarian epithelial, fallopian tube, or primary peritoneal carcinoma~  * Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis and/or regional lymph node metastasis~ * No tumors of borderline or low malignant potential only~ * Mixed Mullerian tumors allowed~* Must have optimal disease defined as no residual lesions after resection or residual disease such that no single lesion measures greater than 1 cm in diameter~* Must have undergone staging exploratory laparotomy with tumor debulking within the past 70 days~PATIENT CHARACTERISTICS:~Age:~* Not specified~Performance status:~* SWOG 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic:~* Bilirubin ≤ 2 times upper limit of normal (ULN)~* SGOT or SGPT ≤ 2 times ULN~Renal:~* Creatinine clearance ≥ 50 mL/min~Cardiovascular:~* No congestive heart failure~* No cardiac arrhythmia~* No myocardial infarction or unstable angina within the past 6 months~* Patients with a history of myocardial disease must not have ischemia or pathologic arrhythmias and must have an ejection fraction \> 50% by MUGA~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No active or uncontrolled infection~* No concurrent fever~* No grade 2 or greater sensory neuropathy~* No severe gastrointestinal symptoms (i.e., partial obstruction) and/or bleeding, diarrhea, or abdominal tenderness suggestive of peritoneal irritation or infection~* No erythema or tenderness of abdominal incision or port site suggestive of underlying infection~* No other malignancy within the past five years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior immunotherapy for ovarian cancer~Chemotherapy:~* No prior chemotherapy for ovarian cancer~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior pelvic radiotherapy for ovarian cancer~Surgery:~* See Disease Characteristics~* Recovered from all reversible surgery-related toxic effects~Other:~* No other concurrent antitumor treatment~* No concurrent antibiotics for infection of undetermined etiology

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel/cisplatin/Liposomal Doxorubicin (Type: EXPERIMENTAL): paclitaxel, cisplatin and liposomal doxorubicin

Based on this trial design, predict the completion outcome and termination type (if applicable).